Filsuvez approved in Great Britain

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization approval for Amryt Pharma’s Filsuvez, a topical gel for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB).  Marketing authorization approval is required before a medicine can be placed on the UK market.

According to the Amryt press release, reimbursement discussions are ongoing, so Filsuvez will not be immediately available. However, this is a great step forward for dystrophic and junctional EB patients.